Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:27 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
NCT02855359 · Seagen Inc. · PHASE2 · terminated · last registry update 2019-03-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision based on portfolio prioritization” | – | Registry record, Seagen Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD19 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-02-07Also stopped (terminated): Abramson Cancer Center at Penn Medicine, Blinatumomab (NCT03173430)
- 2020-02-05Results posted on the registry: MorphoSys AG, Tafasitamab + Lenalidomide (NCT02399085)
- 2020-01-30Results posted on the registry: MorphoSys AG, Tafasitamab + Idelalisib (NCT02639910)
- 2020-01-10Results posted on the registry: Amgen, Blinatumomab (NCT02412306)
- 2019-12-26Results posted on the registry: MedImmune LLC, Inebilizumab (NCT02200770)
- 2019-09-26Results posted on the registry: ADC Therapeutics S.A., ADCT-402 (NCT02669264)
- 2019-09-18Phase 3 first posted: Novartis Pharmaceuticals, CTL019 (NCT04094311)
- 2019-05-22Phase 3 first posted: Children's Oncology Group, Blinatumomab + Calaspargase Pegol (NCT03959085)
- 2019-04-16Phase 3 first posted: National Cancer Institute (NCI), Asparaginase Erwinia chrysanthemi + Blinatumomab (NCT03914625)
- 2018-08-22Phase 3 first posted: Martin Schrappe, Blinatumomab + Bortezomib (NCT03643276)
- 2018-08-14Phase 3 first posted: Novartis Pharmaceuticals, Tisagenlecleucel + Blinatumomab (NCT03628053)
- 2018-07-02Phase 3 first posted: Celgene, Standard of Care + JCAR017 (NCT03575351)
- 2018-06-27Phase 3 first posted: Novartis Pharmaceuticals, Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy + Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT) (NCT03570892)
- 2018-03-26Phase 3 first posted: Amgen, Blinatumomab + Dexamthasone (NCT03476239)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision